First line treatment with omeprazole provides an effective and superior alternative strategy in the management of dyspepsia compared to antacid/alginate liquid: a multicentre study in general practice

Goves, J R; Oldring, J K; Kerr, David; Dallara, R; Roffe, E J; Powell, J. A.; Taylor, Michael D.

doi:10.1046/j.1365-2036.1998.0284f.x

Cited by 56 publications

(33 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The principal outcome from each trial was 'absence of symptoms' but this differed in how many consecutive days without symptoms were classed as 'complete relief'. For example, it was 7 days in Goves and colleagues' study 142 and 15 days in MeinecheSchmidt and Krag's study.…”

Section: Randomisation and Concealment Of Allocationmentioning

confidence: 99%

“…In all analyses, the final end-point was used if possible. In one study, 142 only the data at 2 weeks could be used; after this both groups could receive PPIs. The study by Meineche-Schmidt and Krag 144 145 and Lewin-van den Broek 148 for 24 and 52 weeks, respectively.…”

Section: Randomisation and Concealment Of Allocationmentioning

confidence: 99%

“…All seven trials were RCTs, but only five 142,144,[146][147][148] reported their method of allocation, and only three of these 144,146,147 the mechanism of sequence generation. One study used a centralised telephone randomisation service.…”

Section: Randomisation and Concealment Of Allocationmentioning

confidence: 99%

See 2 more Smart Citations

The management of dyspepsia: a systematic review.

Delaney

Moayyedi²,

Deeks³

et al. 2000

Health Technology Assessment

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK.We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. Competing interests: R Hobbs is a board member of the European Society of Primary Care Gastroenterology, and has received sponsorship for travel and honoraria from a number of biotechnology and pharmaceutical companies for plenary talks and attendance at major scientific congresses and conferences. HTA Published end of 2000This report should be referenced as follows:Delaney B, Moayyedi P, Deeks J, Innes M, Soo S, Barton P, et al. NHS R&D HTA ProgrammeT he NHS R&D Health Technology Assessment (HTA) Programme was set up in 1993 to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS.Initially, six HTA panels (pharmaceuticals, acute sector, primary and community care, diagnostics and imaging, population screening, methodology) helped to set the research priorities for the HTA Programme. However, during the past few years there have been a number of changes in and around NHS R&D, such as the establishment of the National Institute for Clinical Excellence (NICE) and the creation of three new research programmes: Service Delivery and Organisation (SDO); New and ...

show abstract

Section: Randomisation and Concealment Of Allocationmentioning

confidence: 99%

Section: Randomisation and Concealment Of Allocationmentioning

confidence: 99%

See 1 more Smart Citation

The management of dyspepsia: a systematic review.

Delaney

Moayyedi²,

Deeks³

et al. 2000

Health Technology Assessment

View full text Add to dashboard Cite

show abstract

“…In most studies standard doses of H2-blockers were used but the duration of therapy was not longer than 8 wk [18] . Larger studies evaluating higher doses of H2-receptor antagonists and of longer duration may be necessary to determine the exact effect of H2-blockers on functional dyspepsia, but because PPI have been shown to be superior to placebo or H2-blockers in the therapy of functional dyspepsia, it is likely that we will not see major H2-blocker studies for the therapy of dyspepsia in the future [19][20][21][22][23][24][25][26][27] .…”

Section: H Pylori Eradicationmentioning

confidence: 99%

“…Problems with studies evaluating prokinetic agents include small sample size, patient heterogeneity, and poor quality design. Nevertheless, prokinetic agents such as metoclopramide, cisapride, mosapride citrate, itopride hydrochloride and domperidone continue to be widely used for the therapy of functional dyspepsia worldwide [1,2,[27][28][29][30][46][47][48] . Due to its severe cardiac side effects, cisapride is not currently available in most of Europe and North America.…”

Section: Prokinetic Agentsmentioning

confidence: 99%

Drug treatment of functional dyspepsia

Mönkemüller

Malfertheiner

2006

WJG

View full text Add to dashboard Cite

the role of Helicobacter pylori (H pylori ) in functional dyspepsia continues to be a matter of debate, recent data indicate that there is modest but clear benefit of eradication of H pylori in patients with functional dyspepsia. In addition, H pylori is a gastric carcinogen and if found it should be eliminated. Although there are no specific diets for patients with FD, it may be helpful to guide the patients on healthy exercise and eating habits.

show abstract